Navigation Links
MEI Pharma's Mitochondrial Inhibitor Drug Candidate ME-344 Named One of Top 10 Oncology Products for 2012
Date:11/19/2012

cs, Gynecology and Reproductive Sciences at Yale University School of Medicine, presented data at the American Association for Cancer Research Annual Meeting from a pre-clinical study of NV-128 demonstrating its ability to induce mitochondrial instability, ultimately leading to cell death in otherwise chemotherapy-resistant ovarian cancer stem cells. These results were later published in the August 2011 issue of Molecular Cancer Therapeutics. In additional pre-clinical studies, ME-344 demonstrated superior anti-tumor activity against a broad range of human cancer cell lines compared to NV-128.

A Phase I trial of intravenous ME-344 in patients with solid refractory tumors is ongoing. The trial is evaluating the safety and tolerability of intravenous ME-344 in five escalating dose cohorts and is expected to enroll up to 24 patients. Dosing of the fourth cohort (10 mg/kg) is nearly complete; no dose-limiting toxicities have been observed to date. Final safety and pharmacokinetic data is expected in the second quarter of 2013.

MEI Pharma owns exclusive worldwide rights to all of its drug candidates, including ME-344.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor, which has been tested in multiple Phase I and pilot Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome (MDS), acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with azacitidine in patients with MDS by the second quarter of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, M
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
5. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
6. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
7. Global Markets for Enzyme Inhibitors
8. Global Angiogenesis Inhibitors and Stimulators Industry
9. Kinase Inhibitors Market to Reach $11.6 Billion in US, $40.3 Billion Globally by 2016
10. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
11. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group has ... their competitive landscape map for the Chronic Kidney ... 90 international companies with drugs and devices currently ... and its sequelae. (Logo:  ... , hypertension - renal denervation , ...
(Date:5/17/2013)... 17, 2013  Boehringer Ingelheim will contribute to ... the American Thoracic Society International Conference (ATS 2013) ... 17 – 22. Data will highlight ... treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® ... investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) ...
(Date:5/17/2013)... 2013 Sinovac Biotech Ltd. (Nasdaq: SVA ... , today announced that it will release its unaudited ... before market on Tuesday, May 28, 2013.  The Company will ... 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China ... an update on recent corporate developments. To access ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
... 22, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: ... announced today it has filed its Annual Report on Form ... year ended December 31, 2010 on April 22, 2011.  The ... www.sec.gov . The Company will provide a hard ...
... One hundred and eighty miles — Houston to Austin, ... MS 150 overcame on April 16 and 17 in a ... sponsored by The SCOOTER Store , the nation,s leading ... ride and raised nearly $20,000 toward the cause. ...
Cached Medicine Technology:Sinovac Files Annual Report on Form 20-F 2The SCOOTER Store Supports Fight Against Multiple Sclerosis 2
(Date:5/19/2013)... new measure of the heterogeneity the variety of genetic ... treatment outcomes of patients with the most common type of ... of the journal Cancer , investigators at Massachusetts General ... their measure was a better predictor of survival than most ... squamous cell carcinoma of the head and neck. ...
(Date:5/19/2013)... York, NY (PRWEB) May 19, 2013 ... for his two concerts in Vegas in October will ... Additionaly, during the spring and summer months of 2013, ... country. , Whenever people hear “It’s Five O’clock ... hear the voice of Jimmy Buffett inside their heads. Fortunately, ...
(Date:5/19/2013)... A leading symptom of peripheral neuropathy, the ... end through natural ways, such as Neuracel’s Ultimate Support ... number of different underlying problems, the most commonly diagnosed ... is characterized by damage to the peripheral nerves in ... larger system, the peripheral nervous system. The peripheral nervous ...
(Date:5/19/2013)... , , SATURDAY, May 18 (HealthDay News) -- Vitamin ... overcome the fatigue and decreased muscle strength associated ... research. Extra vitamin D "was associated with ... quality of life and the ability to perform ... research dietitian and doctoral candidate at Trinity College ...
(Date:5/19/2013)... Omaha, Nebraska is a city of diversity, ... one of the lowest unemployment rates in the country. Forbes ... Places for Business and Careers and it consistently scores high ... centrally located in the nation and is a strong business ... producers of Editions TV are pleased to announce ...
Breaking Medicine News(10 mins):Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 2Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 3Health News:Jimmy Buffett Las Vegas Tickets: Jimmy Buffett Tickets in Vegas at the MGM Grand on Oct. 19 and Oct. 26 Go on Public Sale Monday, May 20 at 10:00 a.m. Local Time 2Health News:Jimmy Buffett Las Vegas Tickets: Jimmy Buffett Tickets in Vegas at the MGM Grand on Oct. 19 and Oct. 26 Go on Public Sale Monday, May 20 at 10:00 a.m. Local Time 3Health News:Peripheral Neuropathy Naturally Treatable Through Neuracel's Ultimate Neuropathy Support System 2Health News:Extra Vitamin D May Ease Crohn's Symptoms, Study Finds 2Health News:Extra Vitamin D May Ease Crohn's Symptoms, Study Finds 3Health News:Editions TV Announces May Air Dates for Omaha, Nebraska 2
... in breast cancer a master control switch with the ... a cancer-causing gene (or oncogene) named Wnt1. This executive molecule ... on the cover of the August 15 issue of ... of a Wnt oncogene," explains lead author Rakesh Kumar, Ph.D., ...
... By Jenifer Goodwin HealthDay Reporter , ... mistakes, admitting the error, saying "I,m sorry" and offering ... lawsuits, new research shows. In 2001, University ... workers to report medical mistakes. The program included a ...
... The Community Living Assistance Services and Supports (CLASS) Act ... Affordable Care Act has the potential to transform long-term ... an insurance-based system, according to the latest issue of ... ). With funding from The SCAN Foundation , ...
... release is available in French . , Montreal, ... parental monitoring are more likely to befriend deviant peers and ... study published in the journal Addictive Behaviors . Yet ... Sainte-Justine University Hospital Research Center found that bad boys can ...
... Alberta research fellow Amy Speed-Andrews has examined how a specialized ... cancer, and who have completed treatment, makes a difference in ... were asked to fill out a questionnaire about their physical ... of Iyengar yoga and again at the end. After analyzing ...
... Washington engineers are developing the first device able to ... tool is just completing its initial field test by ... hard-of-hearing students. "This is the first study of how ... phones," said project leader Eve Riskin, a UW professor ...
Cached Medicine News:Health News:Researchers identify breast cancer culprits 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 3Health News:CLASS Act analysis reveals America's long-term care future 2Health News:Heavy drug-use among bad boys curbed by parental monitoring and peers 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: